Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

http://hdl.handle.net/2027/mdp.39015072933180



CUMULATIVE SUPPLEMENT 2
AUG'83 - OCT'83

APPROVED PRESCRIPTION DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (◊) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983. The subject product withdrawals are not reflected in this issue of Cumulative Supplement, but will be reflected in Cumulative Supplement 3: August-November, 1983.

Drug products which have been reformulated to exclude phenacetin will appear as they are approved as additions under the appropriate ingredient headings.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '83 (BASELINE)
DRUG PRODUCTS LISTED	6679
SINGLE SOURCE	1908 (28.6%)
MULTISOURCE(1)	4771 (71.4%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)
EXCEPTIONS(2)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-
NUMBER OF APPLICANTS	304

B. ACTIVITY FOR SUPPLEMENT NUMBER 2

	AUG '83	SEPT' 83	OCT '83	CUMULATIVE
DRUG PRODUCTS ADDED:	71	61	37	169
NEWLY APPROVED	70	58	37	165
DESI EFFECTIVE	0	1	0	1
REMARKETED	1	2	0	3
DRUG PRODUCTS REMOVED:	10	26	22	58
WITHDRAWN APPROVAL	0	0	0	0
RX TO OTC SWITCH	0	2	0	2
DISCONTINUED MARKETING	10	24	22	56
NET GAIN IN DRUG PRODUCTS	61	35	15	111
SINGLE SOURCE PRODUCTS APPROVED	8	19	7	34
MULTISOURCE DRUG PRODUCTS APPROVED	63	42	30	135
NEW MOLECULAR ENTITIES APPROVED:	0	1	1	2
AS THE ENTITY	0	0	0	0
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	1	1	2

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (i.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

AMINOPHYLLINE (PAGE 3-8)

/LIQUID; ORAL/
SOLUTION; ORAL
AMINOPHYLLINE
AA ROXANE LABORATORIES 105MG/5ML*

TABLET; ORAL
AMINOPHYLLINE
BD BARR LABORATORIES 100MG*
BD 200MG*
>ADD > AB VANGARD LABS/MWM 100MG*
>ADD > AB 200MG*

>DLT > /AMPHETAMINE SULFATE/(PAGE 3-13)

>DLT > /CAPSULE; CONTROLLED RELEASE; ORAL
>DLT > /BENZEDRINE/
>DLT > /SKAF LABORATORIES/ /15MG/

>DLT > /TABLET; ORAL/
>DLT > /BENZEDRINE/
>DLT > /SKAF LABORATORIES/ /5MG/
>DLT > /10MG/

>ADD > ASPIRIN; BUTALBITAL (PAGE 3-15)

>ADD > TABLET; ORAL
>ADD > AXOTAL
>ADD > ADRIA LABORATORIES 650MG;50MG*

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)

TABLET; ORAL
ASPIRIN AND CAFFEINE W/ BUTALBITAL
PUREPAC/KALIPHARMA 325MG;50MG;40MG*

ASPIRIN; BUTALBITAL; CAFFEINE; PHENACETIN (PAGE 3-15)

TABLET; ORAL
A.P.C. W/ BUTALBITAL
/AA/ /PUREPAC/KALIPHARMA/ /200MG;50MG;40MG;130MG/

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE (PAGE 3-15)

CAPSULE; ORAL
SYNALGOS-DC
IVES LABS/AMHO 356.4MG;30MG;16MG*

ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-15)

CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65
/AA/ /TOWNE PAULSEN/ /227MG;32.4MG;162MG;65MG/
/REPRO COMPOUND 65/
/AA/ /REID-PROVIDENT LABS//227MG;32.4MG;162MG;65MG/
/SK-65 COMPOUND/
/AA/ /SKAF LABORATORIES/ /227MG;32.4MG;162MG;65MG/

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
DARVON COMPOUND-65
AA ELI LILLY INDSTRS/PR 389MG;32.4MG;65MG
>ADD > PROPOXYPHENE COMPOUND 65
>ADD > AA LEMMON 389MG;32.4MG;65MG*
SK-65 COMPOUND
AA SK&F LABORATORIES 389MG;32.4MG;65MG*

ASPIRIN; CARISOPRODOL (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND
WALLACE PHARMS/C-W 325MG;200MG*

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND W/ CODEINE
WALLACE PHARMS/C-W 325MG;200MG;16MG*

ASPIRIN; HYDROCODONE BITARTRATE (PAGE 3-16)

TABLET; ORAL
VICOPRIN
KNOLL PHARMACEUTICAL 500MG;5MG*

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
SPECTROBID
PFIZER LABS/PFIZER 800MG*

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL
>DLT > /PROAQUA/
>DLT > /BP/ /REID-PROVIDENT LABS//50MG/

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL

	BETAMETHASONE VALERATE		
AB	E FOUGERA/BYK-GLDN	EQ 0.1% BASE*	
AB	PHARMADERM/BYK-GLDN	EQ 0.1% BASE*	
	BETATREX		
AB	SAVAGE LABS/BYK-GLDN	EQ 0.1% BASE*	

LOTION; TOPICAL

	BETAMETHASONE VALERATE		
AB	E FOUGERA/BYK-GLDN	EQ 0.1% BASE*	
AB	PHARMADERM/BYK-GLDN	EQ 0.1% BASE*	
	BETATREX		
AB	SAVAGE LABS/BYK-GLDN	EQ 0.1% BASE*	
	VALISONE		
AB	SCHERING	EQ 0.1% BASE	

OINTMENT; TOPICAL

	BETAMETHASONE VALERATE		
AB	E FOUGERA/BYK-GLDN	EQ 0.1% BASE*	
AB	PHARMADERM/BYK-GLDN	EQ 0.1% BASE*	
	BETATREX		
AB	SAVAGE LABS/BYK-GLDN	EQ 0.1% BASE*	
	VALISONE		
AB	SCHERING	EQ 0.1% BASE	

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL

	BROMPHENIRAMINE MALEATE		
>DLI> AA	BOLAR PHARMACEUTICAL	4MG	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION

	MARCAINE HCL W/ EPINEPHRINE		
AP	BREON LABS/STERLING	0.5%;0.0091MG/ML	
AP		0.75%;0.0091MG/ML	
	SENSORCAINE		
AP	ASTRA HOSP PHARM	0.5%;0.0091MG/ML*	
AP		0.75%;0.0091MG/ML*	

CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETIN (PAGE 3-24)

TABLET; ORAL

	SOMA COMPOUND W/ CODEINE		
AB	WALLACE PHARMS/C-W	32MG;200MG;16MG;160MG	

CAFFEINE; CARISOPRODOL; PHENACETIN (PAGE 3-25)

TABLET; ORAL

	SOMA COMPOUND		
AB	WALLACE PHARMS/C-W	32MG;200MG;160MG	

CAFFEINE; ERGOTAMINE TARTRATE (PAGE 3-25)

SUPPOSITORY; RECTAL

		CAFERGOT		
>ADD>	BR	SANDOZ PHARMS/SANDOZ	100MG;2MG	
>ADD>		WIGRAINE		
>ADD>	BR	ORGANON/AKZONA	100MG;2MG*	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/	DEXTROSE 30% IN PLASTIC CONTAINER	
AM MCGAW/AM HOSP	510MG/100ML;30GM/100ML; 200MG/100ML;9.2GM/100ML; 9.6GM/100ML*	
	510MG/100ML;30GM/100ML; 200MG/100ML;9.4GM/100ML; 11GM/100ML*	
DIALYTE CONCENTRATE W/	DEXTROSE 50% IN PLASTIC CONTAINER	
AM MCGAW/AM HOSP	510MG/100ML;50GM/100ML 200MG/100ML;9.2GM/100ML; 9.6GM/100ML*	
	510MG/100ML;50GM/100ML; 200MG/100ML;9.4GM/100ML; 11GM/100ML*	

>ADD> **CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE** (PAGE 3-27)

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER		
AM MCGAW/AM HOSP	35MG/100ML;30MG/100ML; 74MG/100ML;640MG/100ML; 500MG/100ML;74MG/100ML*	

CEFTIZOXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION

CEFIZOX		
SK&F LABORATORIES	EQ 1GM BASE/VIAL*	
	EQ 2GM BASE/VIAL*	

> ADD > CEFUROXIME SODIUM (PAGE 3-30)

> ADD > INJECTABLE; INJECTION
> ADD > ZINACEF
> ADD > GLAXO EQ 750MG BASE/VIAL*
> ADD > EQ 1.5GM BASE/VIAL*

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL
LIBRELEASE
HOFFMANN-LA ROCHE 30MG*

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
> DLT >/AB/ /BOOTS PHARMACEUTICAL/ 5MG/
> DLT >/AB/ /10MG/
> DLT >/AB/ /25MG/

CHLOROTHIAZIDE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE
AB CHELSEA LABORATORIES 250MG*
AB 500MG*

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
/AA/ /JONE PAULSEN/ /4MG/

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL
CHLORTHALIDONE
AB PUREPAC/KALIPHARMA 50MG*

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL
CHLORZOXAZONE
AA PAR PHARMACEUTICAL 250MG*

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
> DLT > /REPOSITORY CORTICOTROPIN/
> DLT > /BC/ /WYETH LABS/AMHO/ /40 UNITS/ML/
> DLT > /BC/ /80 UNITS/ML/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
REDISOL
/AP/ MS&D/MERCK /0.1MG/ML/
SYTOBEX
/AP/ PARKE DAVIS/W-L /0.1MG/ML/

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)

TABLET; ORAL
CYPROHEPTADINE HCL
> ADD > AA DURAMED PHARMS 4MG*

DESOXIMETASONE (PAGE 3-49)

OINTMENT; TOPICAL
TOPICORT
HOECHST-ROUSSEL 0.25%*

DEXAMETHASONE (PAGE 3-49)

SOLUTION; ORAL
DEXAMETHASONE
ROXANE LABORATORIES 0.5MG/5ML*
DEXAMETHASONE INTENSOL
ROXANE LABORATORIES 0.5MG/0.5ML*

TABLET; ORAL
DECADRON
BP MS&D/MERCK 6MG
DEXAMETHASONE
BP ROXANE LABORATORIES 6MG*
1MG*

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)

INJECTABLE; INJECTION
/HEXADROL PHOSPHATE/
HEXADROL
AP ORGANON/AKZONA EQ 4MG PHOSPHATE/ML
EQ 20MG PHOSPHATE/ML

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
/DOPAMINE HCL IN DEXTROSE 5%/
DOPAMINE HCL
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
AP 5GM/100ML;160MG/100ML
DOPAMINE HCL IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML*
AP 5GM/100ML;160MG/100ML*
5GM/100ML;320MG/100ML*

>ADD> DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

>ADD> INJECTABLE; INJECTION
>ADD> HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC
>ADD> CONTAINER
>ADD> TRAVENOL LABS 5GM/100ML;4,000 UNITS/100ML*

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION
>DLT> /DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM/
>ADD> DIATRIZOATE-60

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

TABLET; ORAL
DIETHYLPROPION HCL
AA CAMALL 25MG*

DIMENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION
DIMENHYDRINATE
>DLT> /AP/ /INTL MEDICATION SYS//50MG/ML/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL
SK-DIPHENHYDRAMINE
/AA/ SK&F LABORATORIES /25MG/

ELIXIR; ORAL
>ADD> BELIX
>ADD> AA HALSEY DRUG 12.5MG/5ML*
/SK-DIPHENHYDRAMINE/
/AA/ /SK&F LABORATORIES/ /12.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL
DISULFIRAM
BX CHELSEA LABORATORIES 250MG*
BX 500MG*

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
AB CHELSEA LABORATORIES EQ 50MG BASE

INJECTABLE; INJECTION
>ADD> DOXYCYCLINE
>ADD> AP ELKINS-SINN EQ 100MG BASE/VIAL*
>ADD> AP EQ 200MG BASE/VIAL*
VIBRAMYCIN
>ADD> AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

DROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION
INNOVAR
>DLT> /JANSSEN PHARMA/ /2.5MG/ML;0.05MG/ML/
>ADD> JANSSEN PHARMA 2.5MG/ML;EQ 0.05MG BASE/ML

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 0.01MG/ML;2%*
AP 0.02MG/ML;2%*

ERGOLOID MESYLATES (PAGE 3-66)

CAPSULE; ORAL
>DLT> /HYDERGINE/
>ADD> HYDERGINE LC

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC
ERYTHROMYCIN
AT E FOUGERA/BYK-GLDN 5MG/GM*
AT PHARMADERM/BYK-GLDN 5MG/GM*
ILOTYCIN
AT DISTA PRODS/LILLY 5MG/GM

FENTANYL CITRATE (PAGE 3-75)

INJECTABLE; INJECTION
SUBLIMAZE
>DLT> /JANSSEN PHARMA/ /0.05MG/ML/
>ADD> JANSSEN PHARMA EQ 0.05MG BASE/ML

FLUOXYMESTERONE (PAGE 3-77)

TABLET; ORAL
FLUOXYMESTERONE
>ADD> BP COLMED LABORATORIES 10MG*

GENTAMICIN SULFATE (PAGE 3-79)

CREAM; TOPICAL
GENTAFAIR
AT PHARMAFAIR EQ 1MG BASE/GM*
GENTAMICIN SULFATE
AT NMC LABORATORIES EQ 1MG BASE/GM*

INJECTABLE; INJECTION
GENTAMICIN SULFATE
AP ABBOTT LABORATORIES EQ 60MG BASE/100ML*
AP EQ 70MG BASE/100ML*
AP EQ 80MG BASE/100ML*
AP EQ 90MG BASE/100ML*
AP EQ 100MG BASE/100ML*
AP EQ 1.2MG BASE/ML*
AP EQ 1.4MG BASE/ML*
AP EQ 1.6MG BASE/ML*
AP EQ 1.8MG BASE/ML*
AP EQ 2MG BASE/ML*
AP EQ 10MG BASE/ML*
AP EQ 40MG BASE/ML*
AP LYPHO-MED EQ 40MG BASE/ML*
GENTAMICIN SULFATE IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES EQ 60MG BASE/100ML*
AP EQ 70MG BASE/100ML*
AP EQ 80MG BASE/100ML*
AP EQ 90MG BASE/100ML*
AP EQ 100MG BASE/100ML*
AP EQ 1.2MG BASE/ML*
AP EQ 1.4MG BASE/ML*
AP EQ 1.6MG BASE/ML*
AP EQ 1.8MG BASE/ML*
AP EQ 2MG BASE/ML*
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER
AP TRAVENOL LABS EQ 0.8MG BASE/ML*
AP EQ 80MG BASE/100ML*

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION
/ANTUITRIN S/
/AP/ /PARKE-DAVIS/WL/ /5,000 UNITS/VIAL/

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION
HEPARIN SODIUM
>ADD> AP NATCON 1,000 UNITS/ML*

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL
HOMAPIN-10
/AA/ MISSION PHARMACAL 10MG
/SENS-TENS SE/
/AA/ /LEMMON/ /10MG/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

TABLET; ORAL
HYDRALAZINE HCL
AA PAR PHARMACEUTICAL 100MG*
AA PUREPAC/KALIPHARMA 50MG*

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-87)

TABLET; ORAL
>DLT> /R-HCTZ-H/
>ADD> RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL
>ADD> RESERPINE, HYDRALAZINE HCL, AND HYDROCHLOROTHIAZIDE
>ADD> BP REID-PROVIDENT LABS 25MG;15MG;0.1MG*

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-89)

TABLET; ORAL
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
AB PUREPAC/KALIPHARMA 25MG;25MG*

HYDROCORTISONE (PAGE 3-90)

CREAM; TOPICAL
ELDECORT
>DLT>/AT/ ELDER PHARMS /0.5%/
HYDROCORTISONE
AT BAY LABORATORIES 1%*
AT 2.5%*

HYDROCORTISONE (PAGE 3-90)

LOTION; TOPICAL

		DELACORT	
AT		MERICON INDUSTRIES	0.5%
> ADD >		GLY-CORT	
> ADD >	AT	HERAN PHARMACEUTICAL	1%*
		HYDROCORTISONE	
	AT	MERICON INDUSTRIES	0.5%
AT		TOWNE PAULSEN	0.5%

OINTMENT; TOPICAL

		HYDROCORTISONE	
	AT	BAY LABORATORIES	1%*
	AT		2.5%*

		SOLUTION/DROPS, OPHTHALMIC	
		OPTEF	
		UPJOHN	0.2%

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-92)

SOLUTION/DROPS; OTIC

		NEO-OTOSOL-HC	
	AT	CARTER-GLOGAU LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML*

HYDROCORTISONE ACETATE (PAGE 3-93)

CREAM; TOPICAL

		HYDROCORTISONE ACETATE	
AT		TOWNE PAULSEN	1%

LOTION; TOPICAL

		DRICORT	
AT		INGRAM PHARM	0.5%
		HYDROCORTISONE ACETATE	
AT		TOWNE PAULSEN	0.5%

		SUSPENSION/DROPS, OPHTHALMIC, OTIC	
		HYDROCORTONE	
		MSD/MERCK	2.5%

HYDROCORTISONE VALERATE (PAGE 3-95)

OINTMENT; TOPICAL

		WESTCORT	
		WESTWOOD PHARMS	0.2%*

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL

> ADD >		HYDROFLUMETHIAZIDE AND RESERPINE	
> ADD >	BP	COLMED LABORATORIES	50MG;0.125MG*

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL

		HYDROXYZINE HCL	
	AB	DANBURY PHARMACAL	10MG*
	AB		25MG*
	AB		50MG*

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL

		HYDROXYZINE PAMOATE	
	AB	VANGARD LABS/MWM	EQ 25MG HCL*
	AB		EQ 50MG HCL*

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL

		ANTIPRESS	
BP		LEMMON	25MG
		IMAVATE	
AB		AH ROBINS	25MG
AB			50MG
		IMIPRAMINE HCL	
> ADD >	AB	PAR PHARMACEUTICAL	10MG*
> ADD >	AB		25MG*
> ADD >	AB		50MG*

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION

		ISOETHARINE HCL	
	AN	INTL MEDICATION SYS	0.167%
	AN	ROXANE LABORATORIES	0.167%*
	AN	TRAVENOL LABS	0.25%*

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION

		KANAMYCIN SULFATE	
	AP	INTL MEDICATION SYS	EQ 500MG BASE/2ML*
	AP		EQ 1GM BASE/3ML*
		KANTREX	
AP		BRISTOL LABS/B-N	75MG/2ML
AP			500MG/2ML
AP			1GM/3ML

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION
KANTREX
AP BRISTOL LABS/B-M EQ 75MG BASE/2ML
AP EQ 500MG BASE/2ML
AP EQ 1GM BASE/3ML

LIDOCAINE HYDROCHLORIDE (PAGE 3-104)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 2%

METHYLTESTOSTERONE (PAGE 3-121)

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE
/BP/ /JOHNE PAULSEN/ /10MG/

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
METRO I.V. IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 500MG/100ML%

TABLET; ORAL
METRONIDAZOLE
AB PAR PHARMACEUTICAL 250MG%
AB 500MG%

NANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION
NANDROLONE DECANOATE
>ADD> AQ LEMMON 100MG/ML
>ADD> 50MG/ML
>ADD> AQ LYPHO-MED 100MG/ML%
>ADD> 200MG/ML%
>ADD> AQ MAURRY BIOLOGICAL 100MG/ML%

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
AP G POHL-BOSKAMP 5MG/ML%
1MG/ML%
TRIDIL
AM CRITICAL CARE/AHS 0.5MG/ML%

OXTRIPHYLLINE (PAGE 3-131)

TABLET, ENTERIC COATED; ORAL
CHOLEDYL
AB PARKE-DAVIS/W-L 100MG
AB 200MG
OXTRIPHYLLINE
AB BOLAR PHARMACEUTICAL 100MG%
AB 200MG%

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL
/OXLOPAR/
/AB/ /PARKE-DAVIS/W-L/ /EQ 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL
/UTICILLIN VK/
/AA/ /UPJOHN/ /EQ 125MG BASE/5ML/
/AA/ /EQ 250MG BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-138)

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
AA FERNDALE LABS 35MG%

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL
ADIPEX-P
AA LEMMON 37.5MG%
>ADD> DAPEX-37.5
>ADD> AA FERNDALE LABS 37.5MG%
PHENTERMINE HCL
>ADD> AA CAMALL 37.5MG%

POTASSIUM CHLORIDE (PAGE 3-143)

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
/AP/ /TRAVENOL LABS/ /1MEQ/ML/
/AP/ /3MEQ/ML/
/AP/ /4MEQ/ML/

PREDNISOLONE (PAGE 3-145)

TABLET; ORAL
PREDNISOLONE
> DLT > /BX/ /REXALL DRUG/ /5MG/

PREDNISOLONE ACETATE (PAGE 3-146)

INJECTABLE; INJECTION
> DLT > /FERNISOLONE/
> DLT > /BP/ /FERNDALE LABS/ /25MG/ML/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC
/HYDELTRASOL/
/AT/ /MSD/MERCK/ /EQ 0.5% PHOSPHATE/
METRETON
/AT/ SCHERING EQ 0.5% PHOSPHATE

PREDNISONE (PAGE 3-147)

TABLET; ORAL
PREDNISONE
> ADD > BX DURAMED PHARMS 5MG*
> ADD > BX 10MG*
> ADD > BX 20MG*

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL
PROCAN
/AB/ PARKE-DAVIS/W-L /250MG/
/AB/ /500MG/

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL
PROPOXYPHENE HCL
AA RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL
PROPYLTHIOURACIL
/BD/ /MYLAN PHARMS/ /50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

> DLT > /SYRUP; ORAL/
> DLT > /PSEUDODINE/
> DLT >/AA/ /BAY LABORATORIES/ /30MG/5ML;1.25MG/5ML/
/TRIACIN/
/AA/ /NATL PHARM MFG/BARRE/ 30MG/5ML;1.25MG/5ML/

TABLET; ORAL
/TRIPODRINE/
/AA/ /DANBURY PHARMACAL/ /60MG;2.5MG/
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
AA CHELSEA LABORATORIES 60MG;2.5MG*

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
AB VITARINE/WEST CHEM 300MG*

SECOBARBITAL SODIUM (PAGE 3-160)

CAPSULE; ORAL
SECOBARBITAL SODIUM
> ADD > AA LANNETT 50MG
> ADD > SECONAL SODIUM
> ADD > AA ELI LILLY 50MG*
> ADD > AA 100MG*

SELENIUM SULFIDE (PAGE 3-161)

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT BAY LABORATORIES 2.5%*

SILVER SULFADIAZINE (PAGE 3-161)

CREAM; TOPICAL
/SILVER SULFADIAZINE/
SSD

/SITOSTEROL; ALPHA/(PAGE 3-161)

/SUSPENSION; ORAL/
/CYTELLIN/
/ELI LILLY/ /300/15ML/

SOMATROPIN (PAGE 3-165)

INJECTABLE; INJECTION
ASELLACRIN 2
SERONO LABS 2 IU/VIAL*
/ASELLACRIN/
ASELLACRIN 10

SPIRONOLACTONE (PAGE 3-166)

TABLET; ORAL
SPIRONOLACTONE
AB PUREPAC/KALIPHARMA 25MG*

SULFACETAMIDE SODIUM (PAGE 3-167)

SOLUTION/DROPS; OPHTHALMIC
>ADD > SULFAIR FORTE
>ADD > AT PHARMAFAIR 30%

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION
TESTOSTERONE
CARTER-GLOBAU LABS 50MG/ML*

TETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

CAPSULE; ORAL
TETRACYCLINE HCL
>DLT >/AB/ /LEMMON/ /250MG/

TABLET; ORAL
PANMYCIN
/AB/ UPJOHN /250MG/
SUMYCIN
/AB/ ER SQUIBB AND SONS 250MG

THEOPHYLLINE (PAGE 3-176)

CAPSULE, CONTROLLED RELEASE; ORAL
SOMOPHYLLIN-CRT
BC FISONS 100MG
THEO-24
BC SEARLE/SEARLE PHARMS 100MG*
200MG*
300MG*

SOLUTION; ORAL
THEOLAIR
AA RIKER LABS/3M 80MG/15ML
THEOPHYLLINE
AA ROXANE LABORATORIES 80MG/15ML*

THEOPHYLLINE (PAGE 3-176)

TABLET, CONTROLLED RELEASE; ORAL
THEOCONTIN
BC PURDUE FREDERICK 200MG*
THEO-DUR
BC KEY PHARMACEUTICALS 200MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL
THIORIDAZINE HCL
AA NATL PHARM MFG/BARRE 100MG/ML*

TABLET; ORAL
MELLARIL
AB SANDOZ PHARMS/SANDOZ 100MG
THIORIDAZINE HCL
AB BOLAR PHARMACEUTICAL 10MG*
AB 100MG*
AB CORD LABORATORIES 10MG*
AB 15MG*
AB 25MG*
AB 50MG*
>ADD > AB ZENITH LABORATORIES 100MG*

TIMOLOL MALEATE (PAGE 3-179)

TABLET; ORAL
BLOCADREN
MS&D/MERCK 5MG

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
AT BAY LABORATORIES 0.025%*
AT 0.1%*
AT 0.5%*

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE
AT BAY LABORATORIES 0.025%*
AT 0.1%*
AT 0.5%*

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL
>DLT > /QUAD-RAMOID/
>DLT >/AB/ /ELDER PHARMS/ /500MG/5ML/
/TRISEM/
/AB/ /BEECHAM LABS/BEECHAM/500MG/5ML/

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL
/TRISULFED/
/AA/ /REID-PROVIDENT LABS//500MG/5ML/

TABLET; ORAL
> DLT > /QUADETTS/
> DLT >/AA/ /ELDER PHARMS/ /500MG/
/TRIPLE SULFA #2/
/AA/ /ZENITH LABORATORIES//500MG/

TROPICAMIDE (PAGE 3-186)

SOLUTION/DROPS; OPHTHALMIC
MYDRIAFAIR
AT PHARMAFAIR 0.5%
AI 1%

/TYBAMATE/(PAGE 3-186)

/CAPSULE; ORAL/
/TYBATRAN/
/AH ROBINS/ /250MG/
/350MG/

VITAMIN A PALMITATE (PAGE 3-188)

CAPSULE; ORAL
/SOLVISYN A/
/AA/ /TOWNE PAULSEN/ /EQ 50,000 UNITS BASE/

/CARANIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE; ISOPROPAMIDE/
/IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/CAPSULE; CONTROLLED RELEASE; ORAL/
/TUSS-ORNADE/
/SK&F LABORATORIES/ /20MG;8MG;2.5MG;50MG/

/SOLUTION; ORAL/
/TUSS-ORNADE/
/SK&F LABORATORIES/ /5MG/5ML;2MG/5ML;0.75/5ML;15MG/5ML/

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL
DIPYRIDAMOLE
ASCOT HOSP PHARMS 50MG
>_ADD_> SUPERPHARM 50MG

CURRENT STATUS - INEFFECTIVE

/CARBRITAL/ /PARKE-DAVIS/W-L/
/CARBROMAL; PENTOBARBITAL SODIUM/

CLISTIN RA/ MCNEIL PHARM/
/CARBINOXAMINE MALEATE/

/FORHISTAL/ /CIBA/CIBA-GEIGY/
/DIMETHINDENE MALEATE/

TUSS-ORNADE SK&F LABORATORIES
CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE;
ISOPROPAMIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

☆ U.S. GOVERNMENT PRINTING OFFICE: 1984-421-927:204